PLx Pharma Inc. to Discuss 2021 First Quarter Financial Results on May 14, 2021 Conference Call and Provide Business Update
May 03 2021 - 4:30PM
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a
specialty pharmaceutical company focused on its
clinically-validated and patent-protected PLxGuard™ drug delivery
platform designed to provide more effective and safer products,
with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg
(referred to together as “VAZALORE”), announced today that the
Company will release its 2021 first quarter financial results on
Friday, May 14, 2021, before the U.S. financial markets open.
Natasha Giordano, President and Chief Executive Officer, and
Rita O’Connor, Chief Financial Officer, will host a conference call
to discuss the results and provide a business update as
follows:
Date |
Friday, May 14, 2021 |
Time |
8:30 a.m. ET |
Toll free (U.S.) |
(866) 394-2901 |
InternationalConference ID |
(616) 548-55676238639 |
Webcast (live and replay) |
www.plxpharma.com under the
‘Investor Relations’ section. |
A replay of the conference call will be available for two weeks
after the call's completion by dialing (855) 859-2056 (U.S.) or
(404) 537-3406 (International). The conference ID for the replay is
6238639. The archived webcast will be available for 30 days via the
aforementioned URL.
About VAZALORE VAZALORE is an FDA-approved
liquid-filled aspirin capsule that provides patients with vascular
disease and diabetic patients who are candidates for aspirin
therapy based on physician recommendation, with fast, reliable and
predictable platelet inhibition as compared to enteric-coated
aspirin. It also reduces the risk of stomach erosions and ulcers,
as compared to immediate-release aspirin, common in an acute
setting.
About PLx Pharma Inc.PLx Pharma Inc. is a
specialty pharmaceutical company focused on its
clinically-validated and patent-protected PLxGuard™ drug delivery
platform to provide more effective and safer products. The PLxGuard
drug delivery platform works by targeting the release of active
pharmaceutical ingredients to various portions of the
gastrointestinal (GI) tract. PLx believes this platform has the
potential to improve the absorption of many drugs currently on the
market or in development, and to reduce the risk of stomach
erosions and ulcers associated with certain drugs.
To learn more about PLx Pharma Inc. and its pipeline,
please visit www.plxpharma.com.
Contact Investor Relations:Lisa M. Wilson,
In-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com Source: PLx Pharma Inc.
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Apr 2023 to Apr 2024